Pharmaceutical Market Europe • December 2024 • 44
APPOINTMENTS
Pfizer
Chris Boshoff
Pfizer has appointed Chris Boshoff as chief scientific officer and president, research and development (R&D). Boshoff, who will be taking on the role at the beginning of January, has most recently been serving as the company’s chief oncology officer and executive vice president. In his new position, he will remain a member of Pfizer’s executive leadership team and will lead R&D across all of the company’s therapeutic areas, including oncology. He has spent more than a decade at Pfizer, previously serving as chief development officer for oncology and rare disease, as well as head of development Japan across all therapeutic areas. Boshoff was also previously founding director of the University College London Cancer Institute, and is an elected fellow of the UK Academy of Medical Sciences.
European Medicines Group
Rippon Ubhi
The European Medicines Group has appointed Rippon Ubhi as chair. Ubhi, who will maintain her position as country lead for Sanofi UK and Ireland, holds almost 20 years of senior commercial leadership experience. Prior to joining Sanofi, she spent 18 years at AstraZeneca, culminating in her role as global head of commercial strategy and portfolio, immuno-oncology franchise.
Amgen
Howard Chang
Amgen has appointed Howard Chang as senior vice president of research and chief scientific officer. Chang has extensive experience in human genetics and disease biology. He joins from Stanford University and the Howard Hughes Medical Institute, having co-founded multiple companies, including Cartography Biosciences and Orbital Therapeutics.
Metaphore Biotechnologies
Angela Hwang
Metaphore Biotechnologies has appointed Angela Hwang as chief executive officer. Hwang, who has also been appointed as chief executive officer-partner at Flagship Pioneering, brings extensive experience to the role. She previously worked at Pfizer for almost three decades, most recently serving as chief commercial officer and president of its global biopharmaceuticals business.
DiogenX
Klara Owen
DiogenX has appointed Klara Owen as chief medical officer. Owen has a wealth of experience in the field of diabetes and metabolic disorders. She joins the company from Novo Nordisk, where she served as senior international medical director of cell therapy research and development. Previously, she held the position of medical director at Zealand Pharma.
Kindeva Drug Delivery
Prakash Pandian
Kindeva Drug Delivery has appointed Prakash Pandian as chief information officer. Pandian brings more than 25 years of experience to the role. He most recently served as the global chief information officer at Curia and previously held global leadership roles at Biogen, Millipore Corporation and Merck KgAa.
Bluejay Therapeutics
Roland Gendron
Bluejay Therapeutics has appointed Roland Gendron as senior vice president and head of business development. Gendron holds over 20 years of biotech and corporate development experience and was most recently head of oncology corporate development at Gilead Sciences. Prior to this, he was vice president of business development at CytomX Therapeutics.
Latigo Biotherapeutics
Timothy Walbert
Latigo Biotherapeutics has appointed Timothy Walbert as chair of its board of directors. Walbert has three decades of experience in the biopharmaceutical industry and most recently served as chairman, president and chief executive officer of Horizon Therapeutics. He was also previously president, chief executive officer and director of IDM Pharma.
Bluejay Therapeutics
Eric Dobmeier
Bluejay Therapeutics has appointed Eric Dobmeier as lead independent director. Dobmeier brings significant industry experience to the board. He previously served as president and chief executive officer of Chinook Therapeutics and Silverback Therapeutics, and was chief operating officer at Seagen. He currently serves on the boards of several biotech companies.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services